Eloralintide

Structure: A long-acting synthetic analog of human amylin, the hormone co-secreted with insulin from pancreatic beta cells that signals meal termination. It is engineered for selectivity at the amylin receptors (calcitonin receptor complexed with RAMP proteins), which is the stated difference from Cagrilintide, a dual amylin and calcitonin receptor agonist. Whether that selectivity translates into a better real-world profile is exactly what the current trials are meant to answer.

Dosage:

• No established dose exists. Phase 1 and Phase 2 trials have explored a range of once-weekly SubQ doses with the usual stepwise escalation, and the higher doses produced the greater weight loss.
• Anything circulating with a specific "protocol" attached to it is extrapolation from conference slides, not a published regimen.
• Combination dosing with Tirzepatide is under formal investigation, which is a reasonable indication of where the sponsor thinks the value is.

Administration:

• SubQ, once weekly, insulin syringe
• Standard escalate-slowly logic applies to any incretin or amylin agent, even one with a milder GI profile

Key Notes:

• This is very new, and the honest summary is short. Early trial results reported dose-dependent weight loss over roughly three months in adults with obesity, with adverse event rates, particularly nausea and vomiting, that looked low relative to GLP-1 comparators. Those results were presented at conference and come from small, early-phase studies. There is no Phase 3 data, no long-term safety data, and no outcomes data.
• Do not treat it as a proven better semaglutide. The specific attraction, weight loss without the GI misery, is a real and repeated signal in the amylin class rather than a fluke, but "looked good in Phase 1" is a category of result that frequently does not survive Phase 3.
• Amylin analogs work differently from GLP-1 agonists, and the mechanistic distinction is the reason for the interest. Amylin acts primarily through hindbrain satiety signalling, while GLP-1 agonists engage a broader set of pathways including the ones responsible for the nausea. Some preclinical work suggests amylin analogs may preserve lean mass better than GLP-1 monotherapy, which is directly relevant to anyone dieting for a physique, but this has not been established in humans.
• Availability is the practical problem. An investigational Lilly molecule is not legitimately purchasable. Anything sold under this name is grey-market material of unverifiable identity, and unlike a well-characterised peptide there is no established reference for what correct material even looks like. The realistic risk is that you are injecting something else entirely.
• If you use it alongside exogenous insulin or a sulfonylurea, hypoglycaemia risk increases and doses of those need reducing. Amylin analogs suppress glucagon, which removes part of your counter-regulatory response.
• Slowed gastric emptying affects the absorption of oral compounds taken around the same time, which matters if you are timing orals, and it makes pre-workout nutrition sit heavier.

Bloodwork Monitoring:

• Glucose and HbA1c: baseline and every 12 weeks. Expect improvement. If you are also on insulin, monitor far more closely than that during the escalation.
• Insulin and HOMA-IR: the better markers for tracking whether the weight loss is improving your metabolic health rather than just your scale weight.
• Body Weight: weekly, and pair it with a body composition method you trust. Rapid loss on any appetite suppressant costs lean mass unless protein intake and training are maintained.
• Potassium, Sodium and Magnesium: reduced food intake means reduced electrolyte intake. This is the routine failure point in aggressive dieting on any appetite suppressant.
• ALT, AST and a lipid panel: at 12 weeks, mostly to document the metabolic improvement from the weight loss.
• Creatinine and eGFR: worth including if GI losses or reduced intake leave you chronically underhydrated.